Skip to content

Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth

Normalization of Vitamin D Levels and Its Effect on Glucose Homeostasis in Obese Youth

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02168660
Enrollment
109
Registered
2014-06-20
Start date
2011-03-31
Completion date
2015-10-11
Last updated
2019-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Obesity, Vitamin D Deficiency

Keywords

Obesity, Insulin Resistance, Vitamin D Deficiency, Children, Adolescents

Brief summary

Vitamin D deficiency is extremely common in obese youth. In our obese population followed in the Endocrinology clinic at Children's Medical Center Dallas, vitamin D levels were inversely correlated with a measure of insulin resistance. We propose to show that correction of vitamin D levels in obese children and adolescents improves their insulin sensitivity. Obese youth presenting to the Center for Obesity and its Consequences on Health (COACH) clinic will be randomized to receive either the most recent Institute of Medicine (IOM) recommendations of minimum D3 dose of 600 IU/day (1), or receive higher doses of D3 such that the blood levels of vitamin D will be brought to a target level in either the low part or high part of the normal range. The goal is to determine if correction of vitamin D deficiency will improve insulin sensitivity in this group. Secondary goals include determining whether correction of vitamin D deficiency in obese adolescents and children results in less weight gain, and determining the amount of D3 required to correct vitamin D levels in this population. Our specific hypotheses are as follows: Hypothesis #1 Obese youth treated with Vitamin D3 who achieve low-normal 25-hydroxyvitamin D3 (OHD) levels (30-50 ng/mL) or high-normal 25-OHD levels (60-80 ng/mL) will have improved insulin resistance, as measured by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), compared to those individuals with deficient 25-OHD levels (\< 30 ng/mL). Hypothesis #2 Subjects with a higher BMI will have higher Vitamin D dose requirements than current IOM recommendations of 600 IU/day and will take a longer period of time to reach target 25-OHD levels. Hypothesis #3 Subjects with normal 25-OHD levels will demonstrate less weight gain compared to subjects on the control arm.

Detailed description

Concise Summary of Project: The proposed study is a prospective, unblinded dose-ranging trial to examine in obese youth 1) the effect of correcting Vitamin D (Vit D) deficiency on insulin resistance, 2) the effect of correcting Vit D deficiency on weight gain, and 3) the amount of Vit D3 required to achieve Vit D sufficiency in obese adolescents. Subjects will be recruited from obese children and adolescents aged 6 to 17 years presenting to the COACH clinic, a referral clinic for obese children at Children's Medical Center of Dallas. Approximately 1300 new patients are seen in the COACH clinic each year. Ethnicity will be self-assigned as African-American, Caucasian, Hispanic, or Other. The ethnic makeup of the COACH clinic over the last 20 months was as follows: African-American 25%, Caucasian 19.5%, Hispanic 52%, and Other 3.5%. As per standard practice in the COACH clinic, a height (cm), weight (kg), and blood pressure will be obtained, and body mass index (kg/m2) calculated for each patient. Fasting total cholesterol, LDL, HDL, triglyceride, 25-OHD, Hemoglobin A1c (A1c), and fasting insulin will be obtained, and an Oral Glucose Tolerance Test (OGTT) performed. The baseline estimate of insulin sensitivity is calculated from the fasting insulin and glucose values, and reported as the HOMA-IR. After Informed Consent has been obtained, participants will be randomized to either the Control group (5000 IU/wk), the Low-normal 25-OHD group (target 25-OHD 30-50 ng/mL), or the High-normal 25-OHD group (target 25-OHD 60-80 ng/mL). A 25-OHD \< 25 ng/mL will be confirmed. These groups will be matched for age (6-12 years versus 13-17 years) and ethnicity (Caucasian versus African-American verus Hispanic). Approximately 60 patients will be recruited for each group. Subject participation will continue until Vit D sufficiency has been documented for 4 consecutive months, at which point the fasting insulin and glucose values will be repeated for calculation of HOMA-IR and assessment of insulin sensitivity, and amount of weight gain will be measured.

Interventions

DRUGVitamin D3

Vitamin D3, liquid formulation, 5000 IU/mL.

Sponsors

Perrin C White, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* age 6-17 years * BMI \> 95% for age * serum 25-OH D level \< or + to 25 ng/mL

Exclusion criteria

* BMI \< 95% for age * serum 25-OH D level \> 25 ng/mL * current Vitamin D supplementation \> 400 IU/day * anti-convulsant therapy, anti-hypertensive therapy, lipid lowering medication * any medications that affect glucose metabolism (e.g., metformin, insulin) * daily glucocorticoid therapy * diabetes * any disorders of bone or calcium metabolism * hepatic or renal disease * any malabsorptive disorder * baseline serum Calcium \> 11 ng/dL (\> 2 SD above the mean) * any genetic disorder that predisposes to obesity (e.g., Prader Willi * hypothalamic obesity

Design outcomes

Primary

MeasureTime frameDescription
Change in HOMA-IR4-12 mo after randomization (4 months after target 25-hydroxyvitamin D level is reached).Change in HOMA-IR from initial visit to end-of-study visit; i.e., the value at the later time point minus the value at the earlier time point. HOMA-IR= Fasting insulin (mIU/ml) x Fasting glucose (mg/dl) / 405.

Secondary

MeasureTime frameDescription
Time to Normalization of Vit D Level Versus BMI Z Score1 to 12 monthsThe time required to reach a normal Vitamin D level (\> 30) versus BMI Z score at each vitamin D3 dose; OR vitamin D level at 6 weeks versus BMI Z score at each starting vitamin D3 dose.
Change in BMI Z-score4-12 mo after randomization (4 months after target 25-hydroxyvitamin D level is reached).The change in BMI z-score from baseline to end-of-study visit; i.e., the value at the later time point minus the value at the earlier time point. The BMI Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched children). Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population.

Countries

United States

Participant flow

Participants by arm

ArmCount
Control Group
Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OH D level. Vitamin D3: Vitamin D3, liquid formulation, 5000 IU/mL.
22
Low-Normal Group
Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level). Vitamin D3: Vitamin D3, liquid formulation, 5000 IU/mL.
18
High-Normal Group
Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, De3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level). Vitamin D3: Vitamin D3, liquid formulation, 5000 IU/mL.
21
Total61

Baseline characteristics

CharacteristicControl GroupLow-Normal GroupHigh-Normal GroupTotal
Age, Categorical
<=18 years
22 Participants18 Participants21 Participants61 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants0 Participants
Age, Continuous12 years12 years13 years12 years
Ethnicity (NIH/OMB)
Hispanic or Latino
17 Participants16 Participants15 Participants48 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants2 Participants6 Participants13 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
2 Participants1 Participants5 Participants8 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants2 Participants
Race (NIH/OMB)
White
19 Participants16 Participants16 Participants51 Participants
Region of Enrollment
United States
22 participants18 participants21 participants61 participants
Sex: Female, Male
Female
9 Participants10 Participants10 Participants29 Participants
Sex: Female, Male
Male
13 Participants8 Participants11 Participants32 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 220 / 180 / 21
other
Total, other adverse events
0 / 221 / 180 / 21
serious
Total, serious adverse events
0 / 220 / 180 / 21

Outcome results

Primary

Change in HOMA-IR

Change in HOMA-IR from initial visit to end-of-study visit; i.e., the value at the later time point minus the value at the earlier time point. HOMA-IR= Fasting insulin (mIU/ml) x Fasting glucose (mg/dl) / 405.

Time frame: 4-12 mo after randomization (4 months after target 25-hydroxyvitamin D level is reached).

Population: Beginning and ending anthropometric data were available within the specified time limits on 61 subjects and 25-hydroxyvitamin D3 (25-OHD) levels on 45. Corresponding insulin and glucose data (allowing calculation of HOMA-IR) were available on only 26 subjects, mainly because many 25-OHD levels were obtained when subjects were not fasting.

ArmMeasureValue (MEDIAN)
Control GroupChange in HOMA-IR0 HOMA-IR score
Low-Normal GroupChange in HOMA-IR-1.5 HOMA-IR score
High-Normal GroupChange in HOMA-IR-1.7 HOMA-IR score
Secondary

Change in BMI Z-score

The change in BMI z-score from baseline to end-of-study visit; i.e., the value at the later time point minus the value at the earlier time point. The BMI Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched children). Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population.

Time frame: 4-12 mo after randomization (4 months after target 25-hydroxyvitamin D level is reached).

ArmMeasureValue (MEDIAN)
Control GroupChange in BMI Z-score0.03 z-score
Low-Normal GroupChange in BMI Z-score-0.07 z-score
High-Normal GroupChange in BMI Z-score-0.03 z-score
Secondary

Time to Normalization of Vit D Level Versus BMI Z Score

The time required to reach a normal Vitamin D level (\> 30) versus BMI Z score at each vitamin D3 dose; OR vitamin D level at 6 weeks versus BMI Z score at each starting vitamin D3 dose.

Time frame: 1 to 12 months

Population: Timing of sample collections was too irregular to permit analysis.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026